OncoMatch/Clinical Trials/NCT06179888
Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma
Is NCT06179888 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Iberdomide for multiple myeloma.
Treatment: Iberdomide — This phase II trial compares iberdomide maintenance therapy to disease monitoring for improving survival in patients who have received idecabtagene vicleucel (a type of chimeric antigen receptor T-cell \[CAR-T\] therapy) for multiple myeloma. The usual approach after treatment with idecabtagene vicleucel is to monitor the multiple myeloma without giving myeloma medications. There is currently no medication approved specifically for use after idecabtagene vicleucel treatment. Upon administration, iberdomide modifies the immune system and activates immune cells called T-cells, which could enhance the effectiveness of idecabtagene vicleucel. Iberdomide may keep multiple myeloma under control for longer than the usual approach (disease monitoring) after idecabtagene vicleucel, and may help multiple myeloma patients live longer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: CAR-T cell therapy (idecabtagene vicleucel) — within 80-110 days of registration
All patients are required to have received ide-cel CAR-T within 80-110 days of registration
Must have received: proteasome inhibitor
this includes proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody
Must have received: immunomodulatory agent
this includes proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody
Must have received: anti-CD38 monoclonal antibody
this includes proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody
Cannot have received: iberdomide (iberdomide)
Exception: prior iberdomide refractoriness is prohibited
Prior therapy with iberdomide is permitted but prior iberdomide refractoriness is prohibited
Cannot have received: any MM-directed therapy since ide-cel infusion
Exception: short-course steroids for managing ide-cel toxicity allowed
Patients who have received MM-directed therapy since ide-cel infusion are not eligible, with the exception of short-course steroids for managing ide-cel toxicity
Lab requirements
Blood counts
ANC ≥ 1,500/mm^3; Platelet count ≥ 75,000/mm^3; Platelet transfusions or growth factors not permitted to meet criteria
Kidney function
Calculated creatinine clearance ≥ 30 mL/min by MDRD
Liver function
Total bilirubin ≤ 1.5 x upper limit of normal (ULN); AST/ALT ≤ 3 x ULN
ANC ≥ 1,500/mm^3; Platelet count ≥ 75,000/mm^3; Calculated creatinine clearance ≥ 30 mL/min by MDRD; Total bilirubin ≤ 1.5 x ULN; AST/ALT ≤ 3 x ULN; Platelet transfusions or use of growth factors for neutropenia are not permitted to meet enrollment criteria
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care · Irvine, California
- Cedars Sinai Medical Center · Los Angeles, California
- UC Irvine Health/Chao Family Comprehensive Cancer Center · Orange, California
- University of California Davis Comprehensive Cancer Center · Sacramento, California
- Augusta University Medical Center · Augusta, Georgia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify